Bogart Wealth LLC raised its position in GlaxoSmithKline plc (NYSE:GSK) by 11.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,495 shares of the pharmaceutical company’s stock after buying an additional 4,310 shares during the period. GlaxoSmithKline accounts for 0.9% of Bogart Wealth LLC’s investment portfolio, making the stock its 28th biggest holding. Bogart Wealth LLC’s holdings in GlaxoSmithKline were worth $1,436,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of GSK. Renaissance Technologies LLC increased its stake in GlaxoSmithKline by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares during the last quarter. FMR LLC increased its stake in GlaxoSmithKline by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after buying an additional 1,389,238 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its stake in GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after buying an additional 569,600 shares during the last quarter. Point72 Asset Management L.P. increased its stake in GlaxoSmithKline by 504.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 604,419 shares of the pharmaceutical company’s stock valued at $24,539,000 after buying an additional 504,419 shares during the last quarter. Finally, Seatown Holdings Pte. Ltd. purchased a new stake in GlaxoSmithKline in the 3rd quarter valued at about $20,148,000. Hedge funds and other institutional investors own 9.82% of the company’s stock.
In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.
Several equities research analysts have commented on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Cowen set a $38.00 price target on shares of GlaxoSmithKline and gave the stock a “hold” rating in a research note on Monday, December 11th. Finally, Argus decreased their price target on shares of GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a research note on Thursday, November 30th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $38.57.
Shares of GlaxoSmithKline plc (NYSE GSK) opened at $36.40 on Thursday. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53. The stock has a market cap of $89,240.00, a P/E ratio of 28.22, a PEG ratio of 2.15 and a beta of 0.97.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. The ex-dividend date is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.54%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 154.26%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/bogart-wealth-llc-has-1-44-million-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.